Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical

Dong, Rong; Yan, Youyou; Zeng, Xiaokang; Lin, Nengming; Tan, Biqin

doi:10.2147/dddt.s377697

Cited by 15 publications

(9 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite over a decade of research, the biological mechanisms underlying ibrutinib cardiotoxicity remain unclear. Dong et al hypothesized multiple mechanisms with both on- and off-target effects of ibrutinib ( Dong et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

Mascolo,

Di Napoli,

Balzano

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is authorized for the treatment of chronic lymphocytic leukemia (CLL). This study aims to explore the cardiac safety profile of ibrutinib in comparison with obinutuzumab.Methods: A retrospective pharmacovigilance study was conducted on data retrieved from the European pharmacovigilance database (Eudravigilance) from 1 January 2014 to 30 September 2022. To compare the reporting frequency of cardiovascular events among ibrutinib, obinutuzumab, and the combination of both.Results: A total of 2 291 CV cases were retrieved, of which 1965 were related to ibrutinib, 312 to obinutuzumab, and 14 to the combination. Most cases referred to patients aged ≥65 years (N = 1,454; 63.47%) and male (N = 1,497; 65.34%). Most cases were serious (N = 2,131; 93.02%). The most reported events were: atrial fibrillation (N = 913; 31.31%) and haemorrhage (N = 201; 6.89%). A higher reporting frequency of CV events was found when ibrutinib was compared to obinutuzumab (ROR, 3.22; 95% CI, 2.89-3.60) or combination (ROR, 1.77; 95% CI, 1.11-2.83). A lower reporting was observed when obinutuzumab was compared to combination (ROR, 0.55; 95% CI, 0.34-0.88).Discussion: A higher reporting frequency of CV events in patients exposed to ibrutinib in comparison with obinutuzumab was found. Further studies are needed to better explore the safety of ibrutinib.

show abstract

Section: Discussionmentioning

confidence: 99%

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

Mascolo,

Di Napoli,

Balzano

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“… 27 , 28 , 29 , 32 The newer-generation BTKis, acalabrutinib and zanubrutinib, are associated with improved safety, including reduced frequency of cardiotoxicity, in patients with indolent NHL and chronic lymphocytic lymphoma (CLL). 33 , 34 , 35 Another BTKi, pirtobrutinib, was recently approved for the treatment of R/R MCL after at least two lines of systemic therapy including a BTKi, based on results from a phase 1/2 clinical trial; patients with MCL who were BTKi-experienced achieved an ORR of 54%. 36 , 37 While parsaclisib demonstrated significant and durable responses in BTKi-naive patients, it did not demonstrate significant clinical benefit in patients who received prior BTKi therapy.…”

Section: Discussionmentioning

confidence: 99%

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study

et al. 2023

View full text Add to dashboard Cite

“…Tyrosine kinase inhibitor [28,29] Dalafenib/dasatinib/lapatinib/pasopenib/ponatinib/ sorafenib/trametinib Myocardial ischemia/myocardial infarction/ dypertension/dyspnea/arrhythmia…”

Section: Drug Classificationmentioning

confidence: 99%

Cancer treatment-related cardiotoxicity: a focus on sacubitril/valsartan

Feng

Chen

et al. 2023

Cardiology Plus

View full text Add to dashboard Cite

Cardiotoxicity is the most dramatic complication of cancer therapies, and it results in the cessation of potentially life-saving antitumor treatment regimens and a poor survival prognosis in a nonnegligible proportion of patients. Angiotensin converting enzyme inhibitors (ACEIs) and β-blockers are effective in the treatment of cancer therapy-related cardiac dysfunction (CTRCD), whereas their roles in the prevention of cardiotoxicity are unclear. Sacubitril/valsartan, which is an angiotensin receptor-neprilysin inhibitor, has been shown to be advantageous over ACEIs in heart failure patients with reduced ejection fraction for further the reduction of cardiovascular death or rehospitalization. However, patients with CTRCD were excluded from pivotal trials involving sacubitril/valsartan. Although several small observational studies have observed excellent performance in improving cardiac structure and function in patients with CTRCD, large-scale prospective clinical studies are required to confirm these results. In this review, we described the contemporary literature concerning the potential benefit of sacubitril/valsartan in the cardio-oncology setting.

show abstract

Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical

Cited by 15 publications

References 139 publications

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study

Cancer treatment-related cardiotoxicity: a focus on sacubitril/valsartan

Contact Info

Product

Resources

About